From GlobeNewswire: 2025-04-23 19:00:00

Ascentage Pharma announced that results from two clinical studies of lisaftoclax and alrizomadlin have been selected for presentations at the 2025 ASCO Annual Meeting. The presentations will include updated results from a Phase Ib/II study of a lisaftoclax combination regimen in patients with myeloid malignancies. The ASCO Annual Meeting will take place online and in-person at McCormick Place, Chicago, IL on May 30–June 3. The studies to be presented include a Phase 1b/2 study of lisaftoclax combined with azacitidine in patients with myeloid malignancies, and a phase 2 study of alrizomadlin in patients with advanced adenoid cystic carcinoma or other solid tumors.



Read more at GlobeNewswire: Ascentage Pharma To Present Data from Two Clinical Studies